Frequently Asked Questions

The Revised Schedule M was notified in March 2025. Manufacturers have been given a transition period to comply with the new requirements. Large manufacturers typically have 12 months, while small and medium enterprises may have an extended timeline. Check the official CDSCO notification for specific compliance deadlines.

All manufacturers holding a drug manufacturing license under the Drugs and Cosmetics Act must comply. This includes manufacturers of APIs, finished pharmaceutical products, intermediates, and biological products. Both domestic manufacturers and those exporting from India are covered.

A BMR must contain: product name and batch number, dates and times of commencement and completion of significant intermediate steps and the final processing, identification (initials) of the operator who performed each significant step, in-process control records, a record of any deviation from the approved procedure with written justification, and the quantity of all materials including lot numbers.

Standard Operating Procedures must be reviewed at least once every two years. However, they should also be updated whenever there is a change in process, equipment, materials, or regulations that affects the procedure. All revisions must go through the formal change control process and be approved by the QA department.

A Deviation is a departure from an approved procedure, standard, or specification during manufacturing. It can be planned (authorized in advance) or unplanned. An OOS result specifically refers to a test result that falls outside the established acceptance criteria during quality control testing. Both require formal investigation and documentation, but OOS investigations have a specific 30-day completion timeline under Revised Schedule M.

Sterile manufacturing areas require HEPA filtration with integrity testing at intervals not exceeding six months, defined air change rates (typically 20+ per hour for Grade B, 6+ for Grade D), maintained pressure differentials between areas of different cleanliness grades, continuous environmental monitoring for particles and microorganisms, and temperature and humidity control within validated ranges.

Schedule M follows WHO classifications: Grade A (highest cleanliness, for critical operations like aseptic filling), Grade B (background environment for Grade A zones), Grade C (for less critical operations in sterile manufacturing), and Grade D (minimum classification for manufacturing environment). Each grade has specific particle count limits both 'at rest' and 'in operation'.

All equipment must undergo Installation Qualification (IQ) — verifying it's installed per specifications, Operational Qualification (OQ) — confirming it operates correctly in all anticipated ranges, and Performance Qualification (PQ) — proving it performs consistently with actual products. Qualification must be completed before routine use. Re-qualification is required at defined intervals and after any significant changes.

QC laboratory equipment must meet the same IQ/OQ/PQ qualification requirements as production equipment. Additionally, all measuring and analytical instruments must be calibrated at defined intervals using certified reference standards. Calibration records must be maintained. Equipment failing calibration must be clearly marked and removed from use until recalibrated.

QA must be an independent function, separate from production. The head of QA has the authority to approve or reject any material, intermediate, or finished product. QA is responsible for reviewing production records, investigating deviations, approving SOPs, conducting stability studies, and overseeing the self-inspection program. QA's core responsibilities cannot be delegated to production or other departments.

Under Revised Schedule M, all OOS investigations must be completed within 30 days of the OOS result being identified. The investigation follows a two-phase approach: Phase 1 is the initial laboratory investigation (checking for obvious errors), and Phase 2 is the comprehensive investigation if Phase 1 doesn't identify the cause. The batch cannot be released until the investigation is satisfactorily completed.

All personnel must receive initial GMP training relevant to their duties and continuing training thereafter. Training must be conducted by qualified individuals. Training effectiveness must be assessed periodically. Detailed records including topic, date, trainer name, and assessment results must be maintained. Personnel in contamination-risk areas need additional specialized training.

Written gowning procedures must be established for each production area based on its cleanliness classification. For Grade A/B areas, personnel must wear sterilized protective clothing including head covering, face masks, gloves, and footwear. The gowning procedure itself must be validated to demonstrate that garments don't introduce unacceptable particulate or microbial contamination levels.

Self-inspections must be conducted at least once every six months. This is a significant change from the previous Schedule M which required annual self-inspections. The inspection team must include experts competent in GMP evaluation, and at least one member must be independent of the area being inspected. Written records of all findings must be maintained.

A formal Corrective and Preventive Action (CAPA) system must be established. All observations from self-inspections, complaints, deviations, recalls, and regulatory inspections must be evaluated through CAPA. The effectiveness of corrective actions must be verified, and preventive actions must be implemented to stop recurrence. CAPA activities must be documented with timelines and responsibilities.

A Master Formula Record is an authorized document that specifies the starting materials with their quantities and packaging materials, along with a detailed description of the manufacturing procedure and precautions. It serves as the template from which individual Batch Manufacturing Records (BMRs) are prepared. Any changes to the Master Formula must go through formal change control.

Calibration must be performed at defined intervals using certified reference standards. While Schedule M doesn't specify exact frequencies for all equipment, the intervals must be based on the equipment manufacturer's recommendations, regulatory requirements, and the criticality of the measurement. Typical frequencies range from daily checks for critical instruments to annual recalibration for less critical ones.

Storage areas must have sufficient capacity for orderly storage with proper separation. Separate designated areas are required for quarantined materials, approved materials, rejected materials, recalled products, and returned products. Special attention must be given to highly active materials, narcotics, dangerous drugs, and substances with fire/explosion risks. Temperature and humidity must be controlled and monitored.

While certain testing activities may be outsourced to approved contract laboratories, the overall QC responsibility cannot be delegated. The QC department must maintain oversight of all outsourced testing, including audit rights of contract labs. Similarly, the QA department's core regulatory responsibilities for batch release and document review cannot be outsourced.

Key changes include: self-inspection frequency increased from annual to semi-annual, new requirements for equipment qualification (IQ/OQ/PQ), mandatory cleaning validation, formal CAPA system, 30-day OOS investigation timeline, stricter HVAC requirements, enhanced personnel training records, QA independence requirements, mandated process validation with three consecutive batches, and comprehensive gowning validation.

Production areas must be adequate in size for orderly equipment placement and material flow. Walls, floors, and ceilings must be smooth, crack-free, with coved junctions for easy cleaning. Surfaces must not shed particles and must be easy to clean and disinfect. Cross-contamination prevention through proper layout and segregation is mandatory.

A formal documented change control system is required for evaluating, approving, and recording changes to validated systems, processes, equipment, or materials that may affect product quality. Changes must be initiated through a written proposal, risk-assessed, approved by QA, implemented with proper documentation, and verified for effectiveness. All change records must be maintained.

Ongoing stability studies must be conducted to monitor product quality throughout its shelf life. This includes testing at defined intervals using validated methods. Results must be reviewed by QA and compared against specifications. Any out-of-trend results must be investigated. Stability data forms the basis for assigned shelf life and storage conditions.

Schedule M primarily applies to allopathic (modern) medicines including APIs, FPPs, biologicals, and intermediates. Ayurvedic, Siddha, and Unani medicines have separate GMP requirements under Schedule T of the Drugs and Cosmetics Act. Homeopathic medicines have their own set of standards. However, the principles of GMP are universal.